• Je něco špatně v tomto záznamu ?

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

MC. Fontana, G. Marconi, JDM. Feenstra, E. Fonzi, C. Papayannidis, A. Ghelli Luserna di Rorá, A. Padella, V. Solli, E. Franchini, E. Ottaviani, A. Ferrari, C. Baldazzi, N. Testoni, I. Iacobucci, S. Soverini, T. Haferlach, V. Guadagnuolo, L....

. 2018 ; 32 (7) : 1609-1620. [pub] 20180223

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028552
E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 29472722
DOI 10.1038/s41375-018-0035-y
Knihovny.cz E-zdroje

Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in multiple fragments and consequent random rejoining and repair. This study defines incidence of chromothripsis in 395 newly diagnosed adult acute myeloid leukemia (AML) patients from three institutions, its impact on survival and its genomic background. SNP 6.0 or CytoscanHD Array (Affymetrix®) were performed on all samples. We detected chromothripsis with a custom algorithm in 26/395 patients. Patients harboring chromothripsis had higher age (p = 0.002), ELN high risk (HR) (p < 0.001), lower white blood cell (WBC) count (p = 0.040), TP53 loss, and/or mutations (p < 0.001) while FLT3 (p = 0.025), and NPM1 (p = 0.032) mutations were mutually exclusive with chromothripsis. Chromothripsis-positive patients showed a worse overall survival (OS) (p < 0.001) compared with HR patients (p = 0.011) and a poor prognosis in a COX-HR optimal regression model. Chromothripsis presented the hallmarks of chromosome instability [i.e., TP53 alteration, 5q deletion, higher mean of copy number alteration (CNA), complex karyotype, alterations in DNA repair, and cell cycle] and focal deletions on chromosomes 4, 7, 12, 16, and 17. CBA. FISH showed that chromothripsis is associated with marker, derivative, and ring chromosomes. In conclusion, chromothripsis frequently occurs in AML (6.6%) and influences patient prognosis and disease biology.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028552
003      
CZ-PrNML
005      
20190815105435.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-018-0035-y $2 doi
035    __
$a (PubMed)29472722
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Fontana, Maria Chiara $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy. mariachiara.fontana4@unibo.it.
245    10
$a Chromothripsis in acute myeloid leukemia: biological features and impact on survival / $c MC. Fontana, G. Marconi, JDM. Feenstra, E. Fonzi, C. Papayannidis, A. Ghelli Luserna di Rorá, A. Padella, V. Solli, E. Franchini, E. Ottaviani, A. Ferrari, C. Baldazzi, N. Testoni, I. Iacobucci, S. Soverini, T. Haferlach, V. Guadagnuolo, L. Semerad, M. Doubek, M. Steurer, Z. Racil, S. Paolini, M. Manfrini, M. Cavo, G. Simonetti, R. Kralovics, G. Martinelli,
520    9_
$a Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in multiple fragments and consequent random rejoining and repair. This study defines incidence of chromothripsis in 395 newly diagnosed adult acute myeloid leukemia (AML) patients from three institutions, its impact on survival and its genomic background. SNP 6.0 or CytoscanHD Array (Affymetrix®) were performed on all samples. We detected chromothripsis with a custom algorithm in 26/395 patients. Patients harboring chromothripsis had higher age (p = 0.002), ELN high risk (HR) (p < 0.001), lower white blood cell (WBC) count (p = 0.040), TP53 loss, and/or mutations (p < 0.001) while FLT3 (p = 0.025), and NPM1 (p = 0.032) mutations were mutually exclusive with chromothripsis. Chromothripsis-positive patients showed a worse overall survival (OS) (p < 0.001) compared with HR patients (p = 0.011) and a poor prognosis in a COX-HR optimal regression model. Chromothripsis presented the hallmarks of chromosome instability [i.e., TP53 alteration, 5q deletion, higher mean of copy number alteration (CNA), complex karyotype, alterations in DNA repair, and cell cycle] and focal deletions on chromosomes 4, 7, 12, 16, and 17. CBA. FISH showed that chromothripsis is associated with marker, derivative, and ring chromosomes. In conclusion, chromothripsis frequently occurs in AML (6.6%) and influences patient prognosis and disease biology.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a pruhování chromozomů $7 D002871
650    12
$a chromothripsis $7 D000072837
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a akutní myeloidní leukemie $x diagnóza $x genetika $x mortalita $x terapie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a kruhové chromozomy $7 D012303
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Marconi, Giovanni $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy. giovanni.marconi@studio.unibo.it.
700    1_
$a Feenstra, Jelena D Milosevic $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Wien, Austria.
700    1_
$a Fonzi, Eugenio $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Papayannidis, Cristina $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Ghelli Luserna di Rorá, Andrea $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Padella, Antonella $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Solli, Vincenza $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Franchini, Eugenia $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Ottaviani, Emanuela $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Ferrari, Anna $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Baldazzi, Carmen $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Testoni, Nicoletta $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Iacobucci, Ilaria $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy. Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
700    1_
$a Soverini, Simona $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Haferlach, Torsten $u MLL Munich Leukemia Laboratory, Munich, Germany.
700    1_
$a Guadagnuolo, Viviana $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Semerad, Lukas $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and Hospital, Brno, Czech Republic.
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and Hospital, Brno, Czech Republic.
700    1_
$a Steurer, Michael $u Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
700    1_
$a Racil, Zdenek $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and Hospital, Brno, Czech Republic.
700    1_
$a Paolini, Stefania $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Manfrini, Marco $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Cavo, Michele $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Simonetti, Giorgia $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Kralovics, Robert $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Wien, Austria.
700    1_
$a Martinelli, Giovanni $u Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy. giovanni.martinelli2@unibo.it.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 32, č. 7 (2018), s. 1609-1620
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29472722 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190815105703 $b ABA008
999    __
$a ok $b bmc $g 1433701 $s 1067012
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 32 $c 7 $d 1609-1620 $e 20180223 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

    Možnosti archivace